Aparna Pharmaceuticals, a player in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Advanced Drug Intermediates, has announced a significant achievement. 

Its manufacturing facility, Aparna Organics, located in Pydibhimavaram, Srikakulam, Andhra Pradesh, has been awarded the VAI (Voluntary Action Indicated) classification by the United States Food and Drug Administration (USFDA). The facility underwent an audit by the USFDA in September 2023.

Rakesh Reddy, Managing Director of Aparna Pharmaceuticals, expressed pride in the accomplishment, stating, "This clearance is a testament to our team’s relentless pursuit of excellence. Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval."

Following the successful completion of the FDA audit, Aparna Pharmaceuticals has solidified its position as a leading manufacturer of APIs and Advanced Drug Intermediates, gaining global acknowledgment for delivering top-quality products manufactured in adherence to cGMP (current Good Manufacturing Practice) guidelines.

Aparna Pharmaceuticals is a division of the Aparna Group, which encompasses diverse business verticals such as Aparna Constructions, Aparna Enterprises, and Aparna Property Management Services, boasting a group turnover of USD 1 billion.